Floatz logo

Deferasirox

Hemochromatosis

Haukeland University HospitalSmall moleculePhase 4 / ApprovedDormant
BBB
72/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
57/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Hemochromatosis cohort.

Asset / SponsorPhaseRating
DESFERRIOXAMINE B
Boston Children's Hospital
Phase 4BB
Deferasirox
Boston Children's Hospital
Phase 4BB
DESFERRIOXAMINE B
Boston Children's Hospital
Phase 4BB
Hydroxyurea
St. Jude Children's Research Hospital
Phase 3B

Same molecule, other indications

Deferasirox is also rated in:

iron poisoningDormant
A
Indicative ·
82 / 100
View asset →
hemosiderosisDormant
A
Indicative ·
81 / 100
View asset →
beta-thalassemia majorDormant
BBB
Indicative ·
79 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →